




Instance: composition-en-0349e0c03941d2ede34c30a30310b99b
InstanceOf: CompositionUvEpi
Title: "Composition for odomzo Package Leaflet"
Description:  "Composition for odomzo Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/15/1030/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp0349e0c03941d2ede34c30a30310b99b)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - odomzo"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Odomzo is and what it is used for </li>
<li>What you need to know before you take Odomzo </li>
<li>How to take Odomzo </li>
<li>Possible side effects </li>
<li>How to store Odomzo </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What odomzo is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What odomzo is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Odomzo is </p>
<p>Odomzo contains the active substance sonidegib. It is an anti-cancer medicine. </p>
<p>What Odomzo is used for </p>
<p>Odomzo is used to treat adults with a type of skin cancer called basal cell carcinoma. It is used when the 
cancer has spread locally and cannot be treated with surgery or radiation. </p>
<p>How Odomzo works </p>
<p>The normal growth of cells is controlled by various chemical signals. In patients with basal cell carcinoma, 
changes occur to genes controlling a part of this process known as the  hedgehog pathway . This switches on 
signals that make the cancer cells grow out of control. Odomzo works by blocking this process, stopping 
cancer cells from growing and making new cells. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take odomzo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take odomzo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Read the specific instructions given to you by your doctor, particularly on the effects of Odomzo on unborn 
babies. </p>
<p>Read carefully and follow the instructions of the patient brochure and reminder card given to you by your 
doctor. </p>
<p>Do not take Odomzo 
* if you are allergic to sonidegib or any of the other ingredients of this medicine (listed in section 6). 
* if you are pregnant or think you may be pregnant. This is because Odomzo may cause harm or death to 
your unborn baby (see section  Pregnancy ). 
* if you are breast-feeding. This is because it is not known whether Odomzo can pass into your breast 
milk and cause harm to your baby (see section  Breast-feeding ). 
* if you are able to become pregnant but are unable or unwilling to follow the necessary pregnancy 
prevention measures that are listed in the Odomzo Pregnancy Prevention Programme. 
Do not take Odomzo if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist 
before taking Odomzo. </p>
<p>Additional information on the above points can be found in the sections  Pregnancy ,  Breast-feeding , 
 Fertility  and  Contraception for women and men . </p>
<p>Warnings and precautions 
- Odomzo may cause muscle problems. Tell your doctor before taking Odomzo if you have a history of 
muscle cramps or weakness or if you are taking other medicines. Some medicines (e.g. medicines used 
to treat high cholesterol) might increase the risk for muscle problems. Tell your doctor or pharmacist 
immediately if your muscles hurt or you have unexplained muscle cramps or weakness during 
treatment with Odomzo. Your doctor may need to change your dose, or stop your treatment 
temporarily or permanently. 
- You should not donate blood while on treatment with Odomzo and for 20 months after ending your 
treatment. 
- If you are male, you should not donate semen at any time during treatment and for 6 months after the 
final dose. 
- Your doctor will check your skin regularly for another type of cancer called cutaneous squamous cell 
carcinoma (SCC). It is not known whether SCC can be related to treatment with Odomzo. Usually this 
type of cancer appears on sun-damaged skin, does not spread and can be cured. Tell your doctor if you 
notice any changes in your skin. 
- Never give this medicine to anyone else. You should return unused capsules at the end of your 
treatment. Talk to your doctor or pharmacist regarding where to return the capsules. </p>
<p>Blood tests during treatment with Odomzo 
Your doctor will perform blood tests before treatment, and possibly during treatment as well. These tests will 
check the health of your muscles by measuring the levels of an enzyme in your blood called creatine 
phosphokinase. </p>
<p>Children and adolescents (under 18 years of age) 
Odomzo should not be used in children and adolescents below the age of 18. Problems with growing teeth 
and bones were seen with this medicine. Odomzo may cause bones to stop growing in children and 
adolescents. This can also happen after discontinuation of the treatment. </p>
<p>Other medicines and Odomzo 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This 
includes medicines obtained without a prescription and herbal medicines. This is because Odomzo can affect 
the way some medicines work. Some other medicines can also affect how Odomzo works, or make it more 
likely that you will have side effects. </p>
<p>In particular tell your doctor or pharmacist if you are taking any of the following: 
* medicines such as statins and fibric acid derivatives used to treat high cholesterol and lipids 
* vitamin B3, also known as niacin 
* medicines such as methotrexate, mitoxantrone, irinotecan, or topotecan used to treat certain types of 
cancers or other diseases such as severe joint problems (rheumatoid arthritis) and psoriasis 
* medicines such as telithromycin, rifampicin or rifabutin used to treat bacterial infections 
* medicines such as ketoconazole (not including shampoos and creams), itraconazole, posaconazole or 
voriconazole used to treat fungal infections 
* medicines such as chloroquine and hydroxychloroquine used to treat parasitic infections as well as 
other diseases such as rheumatoid arthritis or lupus erythematosus 
* medicines such as ritonavir, saquinavir or zidovudine used to treat AIDS or HIV 
* medicines such as carbamazepine, phenytoin or phenobarbital used to treat acute seizures 
* a medicine called nefazodone used to treat depression 
* a medicine called penicillamine used to treat rheumatoid arthritis 
* a herbal medicine called St. John s wort (also known as Hypericum perforatum) used to treat 
depression. 
If any of the above apply to you or you are not sure, talk to your doctor or pharmacist before taking Odomzo. </p>
<p>These medicines should be used with caution or may need to be avoided during your treatment with 
Odomzo. If you are taking any of these, your doctor might need to prescribe an alternative medicine for you. </p>
<p>During your treatment with Odomzo, you should also tell your doctor or pharmacist if you are prescribed 
another medicine that you were not taking before. </p>
<p>Pregnancy 
Do not take Odomzo if you are pregnant, think you may be pregnant, or are planning to become pregnant 
during your treatment or during the 20 months after your treatment has finished. You must stop taking 
Odomzo and talk to your doctor immediately if you become pregnant or suspect you could be pregnant. 
Odomzo may cause your baby to have severe birth defects or lead to the death of your unborn baby. Specific 
instructions (the Odomzo Pregnancy Prevention Programme) given to you by your doctor contain 
information particularly on the effects of Odomzo on unborn babies. </p>
<p>Breast-feeding 
Do not breast-feed during your treatment or during the 20 months after your treatment has finished. It is not 
known whether Odomzo can pass into your breast milk and cause harm to your baby. </p>
<p>Fertility 
Odomzo may have an impact on fertility in men and women. Talk to your doctor if you plan to have children 
in the future. </p>
<p>Contraception for women and men 
Women 
Before starting Odomzo treatment, ask your doctor if you are able to become pregnant, even if your periods 
have stopped (menopause). It is important to check with your doctor whether there is a risk that you could 
become pregnant. </p>
<p>If you are able to become pregnant: 
* you must take precautions so that you do not become pregnant while taking Odomzo, 
* you must use 2 methods of contraception, one highly effective method and one barrier method (see the 
examples below) while you are taking Odomzo, 
* you must keep using this contraception for 20 months after you have stopped taking Odomzo because 
traces of the medicine remain in the body for a long time. 
Your doctor will discuss with you the best method of contraception for you. </p>
<p>You must use one highly effective method, such as: 
* an intra-uterine device ( the coil  or IUD) 
* surgical sterilisation. </p>
<p>You must also use one barrier method, such as: 
* a condom (with spermicide, if available) 
* a diaphragm (with spermicide, if available). </p>
<p>Your doctor will test you for pregnancy: 
* at least 7 days before starting treatment   to make sure that you are not already pregnant 
* every month during treatment. </p>
<p>During treatment and during the 20 months after your treatment has finished, tell your doctor straight away 
if: 
* you think your contraception has not worked for any reason 
* your periods stop 
* you stop using contraception 
* you need to change contraception </p>
<p>Men 
While you are taking Odomzo, always use a condom (with spermicide, if available) when you have sex with 
a female partner, even if you have had a vasectomy. You must keep doing this for 6 months after your 
treatment has finished. </p>
<p>Tell your doctor straight away if your partner becomes pregnant while you are taking Odomzo and for 
6 months after your treatment has finished. </p>
<p>You should not donate semen during your treatment and for 6 months after your treatment has finished. </p>
<p>Driving and using machines 
Odomzo is not likely to affect your ability to drive or use any tools or machines. Talk to your doctor if you 
are unsure. </p>
<p>Odomzo contains lactose 
Odomzo contains lactose (milk sugar). If you have been told by your doctor that you have an intolerance to 
some sugars, contact your doctor before taking this medicine. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take odomzo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take odomzo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or 
pharmacist if you are not sure. </p>
<p>Taking this medicine 
The recommended dose is 200 mg (1 capsule) a day. 
* Do not eat for 2 hours before taking Odomzo and for 1 hour afterwards. 
* Take your capsule at about the same time each day. This will help you to remember when to take your 
medicine. 
* Swallow the capsule whole. Do not open, chew or crush the capsule. Any contact with the content of 
the capsules should be avoided, as it may have harmful effects. </p>
<p>Do not change your dose without talking to your doctor. Do not exceed the recommended dose prescribed by 
your doctor. If you vomit after you swallow the capsule, do not take any more capsules until your next 
scheduled dose. </p>
<p>How long to take Odomzo 
Keep taking Odomzo for as long as your doctor tells you. If you have questions about how long to take 
Odomzo, talk to your doctor or pharmacist. </p>
<p>If you take more Odomzo than you should 
If you take more Odomzo than you should, or if someone else accidentally takes your medicine, talk to a 
doctor or go to a hospital straight away. Take the medicine and its packaging and leaflet with you. </p>
<p>If you forget to take Odomzo 
If you forget to take a dose of Odomzo, take it as soon you realise. If more than six hours have passed since 
the dose was due to be taken, skip the missed dose, then take the next dose at the scheduled time. Do not take 
a double dose to make up for a forgotten dose. </p>
<p>If you stop taking Odomzo 
Do not stop taking Odomzo without talking to your doctor first. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Odomzo may cause severe birth defects, You must not become pregnant while taking this medicine (see 
 Pregnancy ,  Breast-feeding ,  Fertility  and  Contraception for women and men  in section 2 for more 
information). </p>
<p>Stop taking Odomzo and tell your doctor straight away if you notice any of the following as these could be 
signs of an allergic reaction: 
* difficulty breathing or swallowing 
* swelling of the face, lips, tongue or throat 
* severe itching of the skin, with a red rash or raised bumps. </p>
<p>Some side effects could be serious 
Tell your doctor or pharmacist straight away if you notice any of the following: 
* severe muscle cramps, muscle pain or muscle weakness. These could be signs of a problem called 
rhabdomyolysis, which involves the breakdown of muscle tissue. 
* dark urine, decreased urine output or no urine output. These could be signs that your muscle fibre is 
breaking down, which is harmful to your kidneys. </p>
<p>Other possible side effects 
If any of these side effects become severe, tell your doctor or pharmacist. </p>
<p>Very common: may affect more than 1 in 10 people 
* muscle cramps, muscle pain, pain in the bones, ligaments and tendons 
* absence of menstrual periods 
* diarrhoea or heartburn 
* decreased appetite 
* headache 
* disturbed sense of taste or strange taste in the mouth 
* pain in the belly 
* feeling sick 
* vomiting 
* itching 
* hair loss 
* tiredness 
* pain 
* weight loss. </p>
<p>Common: may affect up to 1 in 10 people 
* upset stomach or indigestion 
* constipation 
* rash 
* abnormal hair growth 
* thirst, not passing much urine, weight loss, dry flushed skin, irritability (possible symptoms of low 
level of fluids in the body, known as dehydration). 
During Odomzo treatment, you may also have some abnormal blood test results. These can alert your 
doctor to possible changes in the function of some parts of your body, for example: 
* high levels of the following enzymes: creatine phosphokinase (muscle function), lipase and/or amylase 
(pancreas function), alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) (liver 
function) 
* high level of creatinine (kidney function) 
* high level of sugar in the blood (known as hyperglycaemia) 
* low level of haemoglobin (needed to transport oxygen in the blood) 
* low level of white blood cells. </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed 
in this leaflet. You can also report side effects directly via the national reporting system listed in 
Appendix V. By reporting side effects you can help provide more information on the safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store odomzo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store odomzo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <ul>
<li>Keep this medicine out of the sight and reach of children. </li>
<li>Do not use this medicine after the expiry date which is stated on the pack and the blister after EXP. 
The expiry date refers to the last day of that month. </li>
<li>Do not store above 30 C. </li>
<li>Store in the original package in order to protect from moisture. </li>
<li>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </li>
</ul>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Odomzo contains 
* The active substance is sonidegib (as phosphate). Each capsule contains 200 mg sonidegib. 
* The other ingredients are: 
* Capsule contents: crospovidone type A, lactose monohydrate (see section 2,  Odomzo contains 
lactose ), magnesium stearate, poloxamer 188, silica, colloidal anhydrous, sodium laurilsulfate. 
* Capsule shell: gelatin, iron oxide red (E172), titanium dioxide (E171). 
* Printing ink: iron oxide black (E172), propylene glycol (E1520), shellac. </p>
<p>What Odomzo looks like and contents of the pack </p>
<p>Odomzo 200 mg capsules are pink and opaque. They are imprinted with  SONIDEGIB 200MG  and 
 NVR . </p>
<p>Odomzo is provided in perforated unit-dose blisters containing 10 x 1 capsule. It is available in pack sizes of 
10 and 30 capsules. </p>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder and Manufacturer </p>
<p>Sun Pharmaceutical Industries Europe B.V. 
Polarisavenue 2132JH Hoofddorp 
Netherlands </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
Sun Pharmaceutical Industries Europe B.V. 
T l/Tel: +31 23 568 55 Lietuva 
Sun Pharmaceutical Industries Europe B.V. 
Tel: +31 23 568 55 <br />
Sun Pharmaceutical Industries Europe B.V. 
 : +31 23 568 55 Luxembourg/Luxemburg 
Sun Pharmaceutical Industries Europe B.V. 
T l/Tel: +31 23 568 55  esk  republika 
Sun Pharmaceutical Industries Europe B.V. 
Tel: +31 23 568 55 Magyarorsz g 
Sun Pharmaceutical Industries Europe B.V. 
Tel.: +31 23 568 55 Danmark 
Sun Pharmaceutical Industries Europe B.V. 
Tlf: +31 23 568 55 Malta 
Sun Pharmaceutical Industries Europe B.V. 
Tel: +31 23 568 55 Deutschland 
Sun Pharmaceuticals Germany GmbH 
Tel: +49 21 440 39 E-mail: info.de@sunpharma.com 
Nederland 
Sun Pharmaceutical Industries Europe B.V. 
Tel: +31 23 568 55 Eesti 
Sun Pharmaceutical Industries Europe B.V. 
Tel: +31 23 568 55 Norge 
Sun Pharmaceutical Industries Europe B.V. 
Tlf: +31 23 568 55 <br />
Sun Pharmaceutical Industries Europe B.V. 
 : +31 23 568 55  sterreich 
Astro-Pharma GmbH 
Tel:  +43 (1) 97 99 Espa a 
Sun Pharma Laboratorios S.L. 
Tel: +34 93 342 78 Polska 
Ranbaxy (Poland) 
Tel.: +48 22 642 07 France 
Sun Pharma France 
T l:+33 1 41 44 44 Portugal 
Sun Pharmaceutical Industries Europe B.V. 
Tel: +31 23 568 55 Hrvatska 
Sun Pharmaceutical Industries Europe B.V. 
Tel.: +31 23 568 55 Rom nia 
Terapia S.A. 
Tel:+40 264 50 15 Ireland 
Sun Pharmaceutical Industries Europe B.V. 
Tel: +31 23 568 55 Slovenija 
Sun Pharmaceutical Industries Europe B.V. 
Tel: +31 23 568 55  sland 
Sun Pharmaceutical Industries Europe B.V. 
S mi: +31 23 568 55 Slovensk  republika 
Sun Pharmaceutical Industries Europe B.V. 
Tel: +31 23 568 55 Italia 
Sun Pharma Italia S.r.l. 
Tel: +39 02 33 49 07 Suomi/Finland 
Sun Pharmaceutical Industries Europe B.V. 
Puh/Tel: +31 23 568 55 <br />
Sun Pharmaceutical Industries Europe B.V. 
 : +31 23 568 55 Sverige 
Sun Pharmaceutical Industries Europe B.V. 
Tel: +31 23 568 55 Latvija 
Sun Pharmaceutical Industries Europe B.V. 
Tel: +31 23 568 55 United Kingdom (Northern Ireland) 
Ranbaxy UK Ltd 
Tel: +44 (0) 208 848 8This leaflet was last revised in </p>
<p>Other sources of information 
Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-0349e0c03941d2ede34c30a30310b99b
InstanceOf: CompositionUvEpi
Title: "Composition for odomzo Package Leaflet"
Description:  "Composition for odomzo Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/15/1030/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp0349e0c03941d2ede34c30a30310b99b)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - odomzo"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse </li>
<li>Det skal du vide, før du begynder at tage Odomzo </li>
<li>Sådan skal du tage Odomzo </li>
<li>Bivirkninger </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What odomzo is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What odomzo is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Hvad er Odomzo? 
Odomzo indeholder det aktive stof sonidegib. Det er medicin mod kræft. </p>
<p>Dette bruges Odomzo til 
Odomzo bruges til at behandle voksne med en type hudkræft, der hedder basalcellecarcinom. Det bruges, når 
kræften har spredt sig lokalt og ikke kan behandles med operation eller strålebehandling. </p>
<p>Sådan virker Odomzo 
Den normale udvikling af celler kontrolleres af forskellige kemiske signaler. Hos patienter med 
basalcellecarcinom opstår der forandringer i genet, der kontrollerer en del af denne proces kaldet "hedgehog-
vejen". Dette aktiverer signalet, som får kræftceller til at vokse ude af kontrol. Odomzo virker ved at blokere 
denne proces, og dermed forhindre kræftceller i at vokse og dele sig. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take odomzo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take odomzo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Følg alle lægens anvisninger omhyggeligt, særligt om Odomzos virkninger på ufødte babyer. </p>
<p>Læs og følg anvisningerne i patientbrochuren og patientkortet, som du får af din læge, grundigt. </p>
<p>Tag ikke Odomzo </p>
<ul>
<li>
<p>hvis du er allergisk over for sonidegib eller et af de øvrige indholdsstoffer i Odomzo (angivet i 
punkt 6). </p>
</li>
<li>
<p>hvis du er gravid eller tror du kan være gravid. Dette skyldes, at Odomzo kan medføre skade eller 
dødsfald for dit ufødte barn (se "Graviditet"). </p>
</li>
<li>
<p>hvis du ammer. Dette skyldes, at det ikke vides, om Odomzo bliver udskilt i brystmælk og dermed kan 
skade barnet (se "Amning"). </p>
</li>
<li>
<p>hvis du kan blive gravid, men ikke kan eller ikke vil tage de nødvendige forholdsregler mod graviditet, 
som er angivet i Odomzos program for svangerskabsforebyggelse. 
Tag ikke Odomzo, hvis noget af ovenstående gælder for dig. Hvis du er i tvivl, skal du tale med din læge 
eller apotekspersonalet, inden du tager Odomzo. </p>
</li>
</ul>
<p>Du kan finde flere oplysninger om ovenstående punkter under overskrifterne “Graviditet", "Amning", 
"Frugtbarhed" og “Prævention til kvinder og mænd". </p>
<p>Advarsler og forsigtighedsregler 
- Odomzo kan give muskelproblemer. Hvis du tidligere har haft muskelkramper eller muskelsvækkelse, 
eller hvis du tager anden medicin, skal du fortælle det til din læge, før du tager Odomzo. Noget 
medicin (fx medicin mod forhøjet kolesterol) kan øge risikoen for muskelproblemer. Fortæl det straks 
til lægen eller apotekspersonalet, hvis du får ondt i musklerne, eller hvis du får uforklarlige 
muskelkramper eller muskelsvækkelse under behandling med Odomzo. Din læge vil måske ændre din 
dosis eller midlertidigt stoppe eller helt afbryde din behandling. 
- Du må ikke give blod, så længe du er i behandling med Odomzo og i 20 måneder, efter at din 
behandling er afsluttet. 
- Som mand må du ikke være sæddonor på noget tidspunkt under behandlingen og i 6 måneder efter den 
sidste dosis. 
- Din læge vil kontrollere din hud regelmæssigt for en anden type kræft, der hedder pladecellecarcinom 
(SCC). Det vides ikke, om der kan være en sammenhæng mellem SCC og behandling med Odomzo. 
Denne type kræft opstår som regel på solskadet hud, spreder sig ikke og kan kureres. Fortæl det til 
lægen, hvis du bemærker forandringer på din hud. 
- Giv aldrig denne medicin til andre. Du skal returnere ubrugte kapsler efter endt behandling. Spørg din 
læge eller apotekspersonalet om, hvor du kan returnere kapslerne. </p>
<p>Blodprøver under behandling med Odomzo 
Din læge vil tage blodprøver før behandlingen og eventuelt også under behandlingen. Blodprøverne bruges 
til at kontrollere dine musklers sundhedstilstand ved at måle indholdet af enzymet kreatinkinase i dit blod. </p>
<p>Børn og unge (under 18 år) 
Odomzo må ikke bruges til børn og unge under 18 år. Problemer med voksende tænder og knogler er set med 
dette lægemiddel. Odomzo kan muligvis stoppe knoglernes vækst hos børn og unge. Dette kan også ske efter 
behandlingens ophør. </p>
<p>Brug af anden medicin sammen med Odomzo 
Fortæl det altid til lægen eller apotekspersonalet, hvis du tager anden medicin, for nylig har taget anden 
medicin eller planlægger at tage anden medicin. Det gælder også medicin, som ikke er købt på recept samt 
naturlægemidler. Dette skyldes, at Odomzo kan påvirke måden medicinen virker på. Visse andre typer 
medicin kan også påvirke Odomzos virkning eller øge risikoen for, at du får bivirkninger. </p>
<p>Fortæl det især til lægen eller apotekspersonalet, hvis du tager en eller flere af følgende: </p>
<ul>
<li>
<p>medicin, som fx statiner og fibrinsyrederivater mod forhøjet kolesterol og lipider </p>
</li>
<li>
<p>B3-vitamin, som også kaldes niacin </p>
</li>
<li>
<p>medicin, som fx methotrexat, mitoxantron, irinotecan eller topotecan mod visse typer af kræft eller 
mod andre sygdomme som leddegigt (rheumatoid arthritis) og psoriasis </p>
</li>
<li>
<p>medicin, som fx telithromycin, rifampicin eller rifabutin mod bakterieinfektioner </p>
</li>
<li>
<p>medicin, som fx ketoconazol (bortset fra shampoo og creme), itraconazol, posaconazol eller 
voriconazol mod svampeinfektioner </p>
</li>
<li>
<p>medicin, som fx chloroquin og hydroxychloroquin mod parasitære infektioner og mod andre 
sygdomme som leddegigt eller lupus erythematose </p>
</li>
<li>
<p>medicin, som fx ritonavir, saquinavir eller zidovudin mod AIDS eller HIV </p>
</li>
<li>
<p>medicin, som fx carbamazepin, phenytoin eller phenobarbital mod akutte krampeanfald </p>
</li>
<li>
<p>medicin, som hedder nefazodon mod depression </p>
</li>
<li>
<p>medicin, som hedder penicillamin mod leddegigt </p>
</li>
<li>
<p>et naturlægemiddel, som hedder perikon (kaldes også Hypericum perforatum) mod depression. 
Hvis noget af ovenstående gælder for dig, eller hvis du er i tvivl, skal du tale med lægen eller 
apotekspersonalet, før du tager Odomzo. </p>
</li>
</ul>
<p>Disse typer medicin skal anvendes med forsigtighed eller skal måske undgås under din behandling med 
Odomzo. Hvis du tager et eller flere af dem, vil din læge måske ordinere et andet lægemiddel til dig. </p>
<p>Under din behandling med Odomzo skal du også fortælle det til lægen eller apotekspersonalet, hvis du får 
ordineret andre lægemidler, som du ikke tog i forvejen. </p>
<p>Graviditet 
Tag ikke Odomzo, hvis du er gravid, har mistanke om, at du er gravid, eller planlægger at blive gravid under 
din behandling eller i de første 20 måneder efter, at din behandling er afsluttet. Du skal straks holde op med 
at tage Odomzo og tale med din læge, hvis du bliver gravid eller tror, du kan være gravid. Odomzo kan give 
alvorlige fosterskader eller være livsfarligt for det ufødte barn. Specifikke anvisninger (Odomzo’s program 
for svangerskabsforebyggelse) givet til dig af din læge indeholder information særligt om virkningen af 
Odomzo på ufødte babyer. </p>
<p>Amning 
Du må ikke amme under behandling eller i de første 20 måneder, efter at din behandling er afsluttet. Det 
vides ikke, om Odomzo bliver udskilt i brystmælk og dermed kan skade barnet. </p>
<p>Frugtbarhed 
Odomzo kan påvirke mænds og kvinders frugtbarhed. Tal med din læge, hvis du har planer om at få børn i 
fremtiden. </p>
<p>Prævention til kvinder og mænd 
Kvinder 
Før du begynder at tage Odomzo, skal du spørge din læge, om du kan blive gravid; også selvom dine 
menstruationer er stoppet (overgangsalder). Det er vigtigt, at du spørger lægen, om der er risiko for, at du 
kan blive gravid. </p>
<p>Hvis du kan blive gravid: </p>
<ul>
<li>
<p>Du skal tage nogle forholdsregler, så du ikke bliver gravid, mens du tager Odomzo. </p>
</li>
<li>
<p>Du skal anvende to præventionsmetoder; en yderst effektiv metode og en barrieremetode (se 
eksemplerne herunder), så længe du tager Odomzo. </p>
</li>
<li>
<p>Du skal blive ved med at anvende denne prævention i 20 måneder efter, at du er holdt op med at tage 
Odomzo fordi der stadig kan være spor tilbage af medicinen i din krop efter lang tid. 
Din læge vil drøfte med dig, hvilken præventionsmetode der passer bedst til dig. </p>
</li>
</ul>
<p>Du skal bruge én yderst effektiv metode, som fx: </p>
<ul>
<li>
<p>spiral </p>
</li>
<li>
<p>kirurgisk sterilisation. </p>
</li>
</ul>
<p>Du skal også bruge en barrieremetode, som fx: </p>
<ul>
<li>
<p>kondom (så vidt muligt med sæddræbende creme) </p>
</li>
<li>
<p>pessar (så vidt muligt med sæddræbende creme). </p>
</li>
</ul>
<p>Din læge vil undersøge om du er gravid: </p>
<ul>
<li>
<p>mindst 7 dage før behandlingen starter - for at være sikker på at du ikke allerede er gravid </p>
</li>
<li>
<p>hver måned under behandlingen. </p>
</li>
</ul>
<p>Under behandlingen og i de første 20 måneder efter, at din behandling er afsluttet, skal du straks fortælle det 
til lægen, hvis: </p>
<ul>
<li>
<p>du tror, din prævention af en eller anden grund ikke har virket </p>
</li>
<li>
<p>dine menstruationer stopper </p>
</li>
<li>
<p>du holder op med at bruge prævention </p>
</li>
<li>
<p>du får behov for at skifte prævention. </p>
</li>
</ul>
<p>Mænd 
Mens du tager Odomzo, skal du altid bruge kondom (så vidt muligt med sæddræbende creme), når du har 
samleje med en kvindelig partner; også selvom du er steriliseret. Det skal du fortsat gøre i 6 måneder efter, at 
din behandling er afsluttet. </p>
<p>Fortæl det straks til lægen, hvis din partner bliver gravid, mens du tager Odomzo og i 6 måneder efter, din 
behandling er afsluttet. </p>
<p>Du må ikke donere sæd under din behandling og i 6 måneder efter, at din behandling er afsluttet. </p>
<p>Trafik- og arbejdssikkerhed 
Det er ikke sandsynligt, at Odomzo vil påvirke din evne til at køre bil eller betjene værktøj eller maskiner. 
Tal med din læge, hvis du er i tvivl. </p>
<p>Odomzo indeholder lactose 
Odomzo indeholder lactose (mælkesukker). Kontakt lægen, før du tager denne medicin, hvis lægen har 
fortalt dig, at du ikke tåler visse sukkerarter. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take odomzo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take odomzo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. Er du i tvivl, så spørg lægen 
eller apotekspersonalet. </p>
<p>Sådan tages medicinen 
Den anbefalede dosis er 200 mg (1 kapsel) om dagen. </p>
<ul>
<li>
<p>Du må ikke spise noget, 2 timer før du tager Odomzo og 1 time efter, at du har taget Odomzo. </p>
</li>
<li>
<p>Tag kapslen på nogenlunde samme tidspunkt hver dag. Det vil gøre det lettere for dig at huske, 
hvornår du skal tage din medicin. </p>
</li>
<li>
<p>Kapslen skal synkes hel. Kapslen må ikke åbnes, tygges eller knuses. Enhver kontakt med kapslernes 
indhold skal undgås, da det kan have skadelige virkninger </p>
</li>
</ul>
<p>Du må ikke ændre din dosis uden at tale med din læge. Den anbefalede dosis, som din læge har ordineret, må 
ikke overskrides. Hvis du kaster op efter, at du har sunket kapslen, må du ikke tage flere kapsler førend din 
næste planlagte dosis. </p>
<p>Så længe skal du tage Odomzo 
Fortsæt med at tage Odomzo, så længe din læge siger, at du skal gøre det. Hvis du har spørgsmål om, hvor 
længe du skal tage Odomzo, skal du tale med din læge eller apotekspersonalet. </p>
<p>Hvis du har taget for meget Odomzo 
Hvis du har taget for meget Odomzo, eller hvis en anden ved et uheld tager din medicin, skal du straks 
kontakte en læge eller tage på hospitalet. Tag medicinen samt emballagen og indlægssedlen med. </p>
<p>Hvis du har glemt at tage Odomzo 
Hvis du glemmer at tage en dosis af Odomzo, skal du tage den, så snart du kommer i tanke om det. Hvis det 
er mere end seks timer efter, at du skulle have taget din dosis, skal du springe den glemte dosis over og tage 
den næste dosis som planlagt. Du må ikke tage en dobbeltdosis som erstatning for den glemte kapsel. </p>
<p>Hvis du holder op med at tage Odomzo 
Du må ikke holde op med at tage Odomzo uden først at tale med din læge. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Odomzo kan give alvorlige fosterskader. Du må ikke blive gravid, mens du tager denne medicin (se flere 
oplysninger i “Graviditet", "Amning", "Frugtbarhed" og “Prævention til mænd og kvinder" i punkt 2). </p>
<p>Hold straks op med at tage Odomzo, og fortæl det til lægen, hvis du bemærker en eller flere af følgende, da 
det kan være tegn på en allergisk reaktion: </p>
<ul>
<li>
<p>problemer med at trække vejret eller synke </p>
</li>
<li>
<p>hævelse af ansigt, læber, tunge eller hals </p>
</li>
<li>
<p>alvorlig hudkløe med rødt udslæt eller knopper. </p>
</li>
</ul>
<p>Nogle bivirkninger kan være alvorlige 
Fortæl det straks til lægen eller apotekspersonalet, hvis du bemærker en eller flere af følgende: </p>
<ul>
<li>
<p>kraftige muskelkramper, muskelsmerter eller muskelsvækkelse. Dette kan være tegn på en lidelse 
kaldet rhabdomyolyse, som medfører nedbrydning af muskelvæv. </p>
</li>
<li>
<p>mørk urin, nedsat urinmængde eller ingen urinproduktion. Dette kan være tegn på, at dine muskelfibre 
nedbrydes, hvilket er skadeligt for dine nyrer. </p>
</li>
</ul>
<p>Andre bivirkninger 
Hvis en eller flere af disse bivirkninger bliver alvorlige, skal du fortælle det til lægen eller apotekspersonalet. </p>
<p>Meget almindelig: Kan forekomme hos flere end 1 ud af 10 personer </p>
<ul>
<li>
<p>muskelkramper, muskelsmerter, smerter i knogler, ledbånd eller sener </p>
</li>
<li>
<p>udebleven menstruation </p>
</li>
<li>
<p>diarré eller halsbrand </p>
</li>
<li>
<p>nedsat appetit </p>
</li>
<li>
<p>hovedpine </p>
</li>
<li>
<p>smagsforstyrrelser eller en mærkelig smag i munden </p>
</li>
<li>
<p>mavesmerter </p>
</li>
<li>
<p>kvalme </p>
</li>
<li>
<p>opkastning </p>
</li>
<li>
<p>kløe </p>
</li>
<li>
<p>hårtab </p>
</li>
<li>
<p>træthed </p>
</li>
<li>
<p>smerte </p>
</li>
<li>
<p>vægttab. </p>
</li>
</ul>
<p>Almindelig: Kan forekomme hos op til 1 ud af 10 personer </p>
<ul>
<li>
<p>uro i maven eller fordøjelsesbesvær </p>
</li>
<li>
<p>forstoppelse </p>
</li>
<li>
<p>udslæt </p>
</li>
<li>
<p>unormal hårvækst </p>
</li>
<li>
<p>tørst, udskiller lille mængde urin, vægttab, tør rød hud, irritabilitet (mulige tegn på for lidt væske i 
kroppen, kaldet dehydrering). </p>
</li>
</ul>
<p>Under behandlingen med Odomzo kan du også få nogle unormale blodprøveresultater. Disse kan advare 
din læge om mulige ændringer i, hvordan dele af din krop fungerer, fx: </p>
<ul>
<li>
<p>høje værdier af følgende enzymer: kreatinkinase (muskelfunktion), lipase og/eller amylase 
(bugspytkirtelfunktion), alaninaminotransferase (ALAT) og/eller aspartataminotransferase (ASAT) 
(leverfunktion) </p>
</li>
<li>
<p>høj kreatininværdi (nyrefunktion) </p>
</li>
<li>
<p>højt blodsukker (kaldes også hyperglykæmi) </p>
</li>
<li>
<p>lav hæmoglobinværdi (nødvendigt for transport af ilt i blodet) </p>
</li>
<li>
<p>lav mængde hvide blodlegemer. </p>
</li>
</ul>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge eller apotekspersonalet. Dette gælder også mulige 
bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også indberette 
bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i Appendiks V. 
Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information om sikkerheden af 
dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store odomzo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store odomzo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <ul>
<li>
<p>Opbevar lægemidlet utilgængeligt for børn. </p>
</li>
<li>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på pakning og blister efter EXP. Udløbsdatoen er 
den sidste dag i den nævnte måned. </p>
</li>
<li>
<p>Må ikke opbevares ved temperaturer over 30 °C. </p>
</li>
<li>
<p>Opbevares i den originale yderpakning for at beskytte mod fugt. </p>
</li>
<li>
<p>Spørg på apoteket, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke smide 
medicinrester i afløbet, toilettet eller skraldespanden. </p>
</li>
</ul>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Odomzo indeholder: </p>
<ul>
<li>
<p>Aktivt stof: sonidegib (som fosfat). Hver kapsel indeholder 200 mg sonidegib. </p>
</li>
<li>
<p>Øvrige indholdsstoffer: </p>
</li>
<li>
<p>Kapselindhold: crospovidon type A, lactosemonohydrat (se pkt. 2 "Odomzo indeholder 
lactose"), magnesiumstearat, poloxamer 188, silica, kolloid vandfrinatriumlaurilsulfat </p>
</li>
<li>
<p>Kapslen: gelatine, jernoxid; rød (E172), titandioxid (E171). </p>
</li>
<li>
<p>Trykfarve: jernoxid; sort (E172), propylenglycol (E1520), shellac. </p>
</li>
</ul>
<p>Udseende og pakningsstørrelser 
Odomzo 200 mg kapsler er lyserøde og uigennemsigtige. De er præget med “SONIDEGIB 200MG" og 
“NVR". </p>
<p>Odomzo fås i perforerede enkeltdosis blistere, der indeholder 10 x 1  kapsel. Produktet fås i 
pakningsstørrelser på 10 og 30 kapsler. </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen og Fremstiller 
Sun Pharmaceutical Industries Europe B.V. 
Polarisavenue 2132JH Hoofddorp 
Holland 
Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale repræsentant 
for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
Sun Pharmaceutical Industries Europe B.V. 
Tél/Tel: +31 23 568 55 Lietuva 
Sun Pharmaceutical Industries Europe B.V. 
Tel: +31 23 568 55<br />
България 
Sun Pharmaceutical Industries Europe B.V. 
Тел: +31 23 568 55 Luxembourg/Luxemburg 
Sun Pharmaceutical Industries Europe B.V. 
Tél/Tel: +31 23 568 55<br />
Česká republika 
Sun Pharmaceutical Industries Europe B.V. 
Tel: +31 23 568 55 Magyarország 
Sun Pharmaceutical Industries Europe B.V. 
Tel.: +31 23 568 55<br />
Danmark 
Sun Pharmaceutical Industries Europe B.V. 
Tlf: +31 23 568 55 Malta 
Sun Pharmaceutical Industries Europe B.V. 
Tel: +31 23 568 55<br />
Deutschland 
Sun Pharmaceuticals Germany GmbH 
Tel: +49 21 440 39 E-mail: info.de@sunpharma.com </p>
<p>Nederland 
Sun Pharmaceutical Industries Europe B.V. 
Tel: +31 23 568 55 Eesti 
Sun Pharmaceutical Industries Europe B.V. 
Tel: +31 23 568 55 Norge 
Sun Pharmaceutical Industries Europe B.V. 
Tlf: +31 23 568 55<br />
Ελλάδα 
Sun Pharmaceutical Industries Europe B.V. 
Τηλ: +31 23 568 55 Österreich 
Astro-Pharma GmbH 
Tel:  +43 (1) 97 99<br />
España 
Sun Pharma Laboratorios S.L. 
Tel: +34 93 342 78 Polska 
Ranbaxy (Poland) 
Tel.: +48 22 642 07<br />
France 
Sun Pharma France<br />
Tél:+33 1 41 44 44 Portugal 
Sun Pharmaceutical Industries Europe B.V. 
Tel: +31 23 568 55<br />
Hrvatska 
Sun Pharmaceutical Industries Europe B.V. 
Tel.: +31 23 568 55 România 
Terapia S.A. 
Tel:+40 264 50 15<br />
Ireland 
Sun Pharmaceutical Industries Europe B.V. 
Tel: +31 23 568 55 Slovenija 
Sun Pharmaceutical Industries Europe B.V. 
Tel: +31 23 568 55<br />
Ísland 
Sun Pharmaceutical Industries Europe B.V. 
Sími: +31 23 568 55 Slovenská republika 
Sun Pharmaceutical Industries Europe B.V. 
Tel: +31 23 568 55<br />
Italia 
Sun Pharma Italia S.r.l. 
Tel: +39 02 33 49 07 Suomi/Finland 
Sun Pharmaceutical Industries Europe B.V. 
Puh/Tel: +31 23 568 55<br />
Κύπρος 
Sun Pharmaceutical Industries Europe B.V. 
Τηλ: +31 23 568 55 Sverige 
Sun Pharmaceutical Industries Europe B.V. 
Tel: +31 23 568 55<br />
Latvija 
Sun Pharmaceutical Industries Europe B.V. 
Tel: +31 23 568 55 United Kingdom (Northern Ireland) 
Ranbaxy UK Ltd 
Tel: +44 (0) 208 848 8 </p>
<p>Denne indlægsseddel blev senest ændret </p>
<p>Andre informationskilder 
Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu </p>
<p>Som led i programmet til forebyggelse af graviditet for patienter, der får Odomzo, vil alle patienter få 
udleveret: </p>
<ul>
<li>
<p>En patientbrochure </p>
</li>
<li>
<p>Et patientkort </p>
</li>
</ul>
<p>Se disse dokumenter for yderligere oplysninger. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-0349e0c03941d2ede34c30a30310b99b
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for odomzo Package Leaflet for language en"
Description: "ePI document Bundle for odomzo Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-0349e0c03941d2ede34c30a30310b99b"
* entry[0].resource = composition-en-0349e0c03941d2ede34c30a30310b99b

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp0349e0c03941d2ede34c30a30310b99b"
* entry[=].resource = mp0349e0c03941d2ede34c30a30310b99b
                            
                    
Instance: bundlepackageleaflet-da-0349e0c03941d2ede34c30a30310b99b
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for odomzo Package Leaflet for language da"
Description: "ePI document Bundle for odomzo Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-0349e0c03941d2ede34c30a30310b99b"
* entry[0].resource = composition-da-0349e0c03941d2ede34c30a30310b99b

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp0349e0c03941d2ede34c30a30310b99b"
* entry[=].resource = mp0349e0c03941d2ede34c30a30310b99b
                            
                    



Instance: mp0349e0c03941d2ede34c30a30310b99b
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Odomzo 200 mg hard capsules"
Description: "Odomzo 200 mg hard capsules"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/15/1030/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Odomzo 200 mg hard capsules"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 0349e0c03941d2ede34c30a30310b99bListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "odomzo"

* status = #current
* mode = #working

* title = "List of all ePIs associated with odomzo"

* subject = Reference(mp0349e0c03941d2ede34c30a30310b99b)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#odomzo "odomzo"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-0349e0c03941d2ede34c30a30310b99b) // odomzo en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-0349e0c03941d2ede34c30a30310b99b) // odomzo da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-0349e0c03941d2ede34c30a30310b99b
InstanceOf: List

* insert 0349e0c03941d2ede34c30a30310b99bListRuleset
    